GlaxoSmithKline PLC
LSE:GSK

Watchlist Manager
GlaxoSmithKline PLC Logo
GlaxoSmithKline PLC
LSE:GSK
Watchlist
Price: 1 339.5 GBX 0.41%
Market Cap: 54.7B GBX
Have any thoughts about
GlaxoSmithKline PLC?
Write Note

GlaxoSmithKline PLC
Depreciation & Amortization

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

GlaxoSmithKline PLC
Depreciation & Amortization Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Depreciation & Amortization CAGR 3Y CAGR 5Y CAGR 10Y
GlaxoSmithKline PLC
LSE:GSK
Depreciation & Amortization
-ÂŁ61m
CAGR 3-Years
13%
CAGR 5-Years
-1%
CAGR 10-Years
4%
AstraZeneca PLC
LSE:AZN
Depreciation & Amortization
-$3.8B
CAGR 3-Years
-27%
CAGR 5-Years
-14%
CAGR 10-Years
N/A
Verona Pharma PLC
NASDAQ:VRNA
Depreciation & Amortization
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Indivior PLC
LSE:INDV
Depreciation & Amortization
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Hikma Pharmaceuticals PLC
LSE:HIK
Depreciation & Amortization
-$90m
CAGR 3-Years
-22%
CAGR 5-Years
-40%
CAGR 10-Years
N/A
Dechra Pharmaceuticals PLC
LSE:DPH
Depreciation & Amortization
-ÂŁ140.2m
CAGR 3-Years
-26%
CAGR 5-Years
-21%
CAGR 10-Years
N/A
No Stocks Found

GlaxoSmithKline PLC
Glance View

Market Cap
54.6B GBX
Industry
Pharmaceuticals

Once upon a time, in the bustling world of pharmaceuticals, GlaxoSmithKline PLC established itself as a formidable player. Born out of mergers and continuous evolution, GSK, as it is commonly known, carved its place in the competitive landscape through strategic research and pioneering innovations. The company operates at the intersection of pharmaceuticals, vaccines, and consumer healthcare, leveraging its breadth to tackle some of the world's most pressing health challenges. From its bustling laboratories to clinical trials, and finally to market, GSK is driven by a mission to improve the quality of human life. Its intricate network of research facilities and production plants stretch across the globe, working tirelessly to develop essential medications and vaccines that span a variety of therapeutic areas including respiratory, HIV, oncology, and immunology. GSK’s revenue streams flow from a well-diversified portfolio. The pharmaceutical division, representing the lion’s share, innovates and produces transformative medicines. Its vaccines division stands strong, leading with essential inoculations that prevent childhood and adult diseases, while the consumer healthcare segment provides everyday wellness products ranging from pain relief to vitamins and skincare. This triad not only underscores GSK’s dynamic adaptability to market needs but also highlights its resilience in weathering the cyclical nature of the healthcare industry. With a keen eye on long-term value and sustained investment in research and development, GSK continues to create a bridge between scientific advancements and societal well-being, defining its role as both a scientific leader and a profit-driven enterprise.

GSK Intrinsic Value
2 344.54 GBX
Undervaluation 43%
Intrinsic Value
Price

See Also

What is GlaxoSmithKline PLC's Depreciation & Amortization?
Depreciation & Amortization
-61m GBP

Based on the financial report for Jun 30, 2024, GlaxoSmithKline PLC's Depreciation & Amortization amounts to -61m GBP.

What is GlaxoSmithKline PLC's Depreciation & Amortization growth rate?
Depreciation & Amortization CAGR 10Y
4%

Over the last year, the Depreciation & Amortization growth was 24%. The average annual Depreciation & Amortization growth rates for GlaxoSmithKline PLC have been 13% over the past three years , -1% over the past five years , and 4% over the past ten years .

Back to Top